Neuland shares jump after Q1 profit surges 975% YoY
In short
Neuland Laboratories shares rose sharply on Thursday after the company said its Q1 FY27 profit jumped 975% year on year to Rs 147.4 crore. The company also said revenue more than doubled and EBITDA rose 448%, helped by strong commercial product sales and better results in its CMS and GDS businesses. In this story, profit means money left after expenses, while EBITDA is a measure of operating earnings before some costs. This matters because the results can move the stock and shape investor views of the drugmaker’s business strength.
What the reporting says
Neuland Laboratories shares rose sharply on Thursday after the drugmaker reported a 975% year-on-year surge in Q1 FY27 profit to Rs 147.4 crore. Revenue more than doubled and EBITDA jumped 448%, with the company citing strong commercial product sales and encouraging performance across its CMS and GDS businesses. The immediate market reaction was a share-price jump; the source does not state any further guidance or outlook.
Why it matters
Neuland Laboratories reported a 975% year-on-year rise in Q1 FY27 profit to Rs 147.4 crore, alongside revenue that more than doubled and EBITDA up 448%. The publisher summary says the gains were driven by strong commercial product sales and better performance in CMS and GDS businesses. Shares rose sharply on Thursday. The sources do not state any updated guidance, pricing impact, or whether the jump will continue.